Uncategorized

NRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression

NRx Pharmaceuticals, Inc., a clinical-stage CNS biopharmaceutical company, reported that the independent Data Safety Monitoring Board reviewed the safety and efficacy findings of the first fifty enrolled participants in the Company’s clinical trial of NRX-101 for the treatment of Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior.

NRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression Read More »

YS Biopharma’s PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical Study

YS Biopharma announced its positive interim Phase II safety and immunogenicity data for its PIKA recombinant COVID-19 Vaccine.

YS Biopharma’s PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical Study Read More »

Scroll to Top